Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.
about
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancerCDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylationBypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer.Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell linesCharacterization of tumor differentiation factor (TDF) and its receptor (TDF-R).Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target.Recent progress in targeting cancer.A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.Adenovirus-Mediated Angiotensin II Type 2 Receptor Overexpression Inhibits Tumor Growth of Prostate Cancer In VivoTargeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer.Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?ARF represses androgen receptor transactivation in prostate cancer.ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.An Sp1 Modulated Regulatory Region Unique to Higher Primates Regulates Human Androgen Receptor Promoter Activity in Prostate Cancer Cells.P53 and the proteasome regulate androgen receptor activity.High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels.Negative regulation of the androgen receptor gene through a primate-specific androgen response element present in the 5' UTR.
P2860
Q24620356-48732532-396D-4708-B2E5-B7217AC72D84Q30429511-38E0310E-7F56-4A66-8D1C-B04232B3E131Q33728239-78DA40C2-8899-44F4-B776-98AF98923EF3Q33745234-9BE0BBE9-70A1-4437-9C91-18AF52B77318Q33988757-562C9750-13C3-4162-9929-CF668E627F92Q34449941-521644DA-B6D1-4746-8C5D-EAF19EF458D3Q34499785-5B8450E7-5391-42A2-A8EE-BCE234E5063DQ35740782-6D819419-9C70-4C1C-BB77-62FB4A520FCEQ36098127-00ACA9EC-06AD-40D6-B80C-D299BE3DA20AQ36473924-30BBD0BA-7596-4EE6-908B-0B4354355755Q36575243-2AB6F401-9FE3-4CA4-B4A6-162FCFE8F6F0Q36661732-5307A253-5C3F-4193-8A0F-F4FFD2BDF62AQ36714871-E787A064-090F-4C70-AFFC-6B2166A47304Q37091948-784AAFE1-E004-4920-B862-8AC0ADB9C3E6Q38820751-E89188C2-E8A2-46EB-8A38-07E514345F11Q38828800-E86166F1-A871-4BCB-A236-4EC0C8060CC7Q38829510-BE1D4B81-EF8F-4C13-8DC7-1934DB9BEFEAQ39381838-7DBA791A-4278-4E0F-8B4C-0D066FB18F87Q39694512-BF8CE862-8AC2-42BD-8C99-C26D6A61F6A6Q39879669-DDF1BDE9-C812-4D15-ABA9-815CA781EE64Q42878519-7CA1AE4D-BD27-4F9A-84AB-72E172D2A35F
P2860
Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Prostate cancer cells tolerate ...... eptor expression and activity.
@en
type
label
Prostate cancer cells tolerate ...... eptor expression and activity.
@en
prefLabel
Prostate cancer cells tolerate ...... eptor expression and activity.
@en
P2093
P2860
P356
P1433
P1476
Prostate cancer cells tolerate ...... eptor expression and activity.
@en
P2093
Andrei V Gudkov
Katerina V Gurova
Natalia D Tararova
Natalya Narizhneva
Vadim Krivokrisenko
P2860
P304
P356
10.1002/PROS.20662
P577
2007-12-01T00:00:00Z